257 related articles for article (PubMed ID: 24144760)
41. Long-term renoprotective effect of combination therapy with prostaglandin E1 and angiotensin-converting enzyme inhibitor in patients with chronic renal failure.
Nakayama Y; Nonoguchi H; Kiyama S; Kohda Y; Inoue T; Tomita K
Hypertens Res; 2005 Sep; 28(9):733-9. PubMed ID: 16419646
[TBL] [Abstract][Full Text] [Related]
42. Effect of chronic dietary protein intake on the renal function in healthy subjects.
Brändle E; Sieberth HG; Hautmann RE
Eur J Clin Nutr; 1996 Nov; 50(11):734-40. PubMed ID: 8933120
[TBL] [Abstract][Full Text] [Related]
43. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people.
Ansquer JC; Dalton RN; Caussé E; Crimet D; Le Malicot K; Foucher C
Am J Kidney Dis; 2008 Jun; 51(6):904-13. PubMed ID: 18501783
[TBL] [Abstract][Full Text] [Related]
44. Effectiveness of beraprost sodium in maintaining vascular access patency in patients on hemodialysis.
Kim M; Kim JU; Kim SM; Kim H
Int Urol Nephrol; 2017 Jul; 49(7):1287-1295. PubMed ID: 28409403
[TBL] [Abstract][Full Text] [Related]
45. A dose-effect study of beraprost sodium in intermittent claudication.
Lievre M; Azoulay S; Lion L; Morand S; Girre JP; Boissel JP
J Cardiovasc Pharmacol; 1996 Jun; 27(6):788-93. PubMed ID: 8761844
[TBL] [Abstract][Full Text] [Related]
46. Abnormalities of coagulation in hypertensive patients with reduced creatinine clearance.
Catena C; Zingaro L; Casaccio D; Sechi LA
Am J Med; 2000 Nov; 109(7):556-61. PubMed ID: 11063957
[TBL] [Abstract][Full Text] [Related]
47. The clinical research on serum cystatin-C alteration on stage II chronic kidney disease with gubenquduyishen decoction treatment.
Dong F; Cheng J; Lin S; Hu Z; Chen G; He L
J Ethnopharmacol; 2010 Oct; 131(3):581-4. PubMed ID: 20659545
[TBL] [Abstract][Full Text] [Related]
48. Effect of long-term administration of prostaglandin I(2) in incipient diabetic nephropathy.
Owada A; Suda S; Hata T
Nephron; 2002 Dec; 92(4):788-96. PubMed ID: 12399622
[TBL] [Abstract][Full Text] [Related]
49. Comparison of clinical and laboratory parameters in patients with end-stage renal failure in the outcome of chronic glomerulonephritis and patients with end-stage renal failure in the outcome of other diseases.
Popova JA; Yadrihinskaya VN; Krylova MI; Sleptsovа SS; Borisovа NV
Wiad Lek; 2016; 69(6):739-741. PubMed ID: 28214807
[TBL] [Abstract][Full Text] [Related]
50. It is time to review concepts on renal involvement in leprosy: pre- and post-treatment evaluation of 189 patients.
Polito MG; Moreira SR; Nishida SK; Mastroianni Kirsztajn G
Ren Fail; 2015 Aug; 37(7):1171-4. PubMed ID: 26099294
[TBL] [Abstract][Full Text] [Related]
51. Effects of frusemide in chronic renal failure.
Keeton GR; Morrison S
Nephron; 1981; 28(4):169-73. PubMed ID: 7301002
[TBL] [Abstract][Full Text] [Related]
52. Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial.
Koyama A; Fujita T; Gejyo F; Origasa H; Isono M; Kurumatani H; Okada K; Kanoh H; Kiriyama T; Yamada S
BMC Nephrol; 2015 Oct; 16():165. PubMed ID: 26475266
[TBL] [Abstract][Full Text] [Related]
53. Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication.
Hashiguchi M; Ohno K; Saito R
Yakugaku Zasshi; 2004 Jun; 124(6):321-32. PubMed ID: 15170067
[TBL] [Abstract][Full Text] [Related]
54. Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients.
Ohtake T; Sato M; Nakazawa R; Kondoh M; Miyaji T; Moriya H; Hidaka S; Kobayashi S
Ther Apher Dial; 2014 Feb; 18(1):1-8. PubMed ID: 24499078
[TBL] [Abstract][Full Text] [Related]
55. The influence of L-tryptophan peroral load on glomerular filtration rate in chronic glomerulonephritis and chronic renal failure.
Martinsons A; Rudzite V; Cernevskis H; Mihailova I; Smeltere Z
Adv Exp Med Biol; 2003; 527():337-45. PubMed ID: 15206747
[TBL] [Abstract][Full Text] [Related]
56. [Clinical study on niaodujing in treating chronic renal failure].
Wang YJ; Xu L; Cheng XX
Zhongguo Zhong Xi Yi Jie He Za Zhi; 1996 Nov; 16(11):649-51. PubMed ID: 9772612
[TBL] [Abstract][Full Text] [Related]
57. Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or nephrosclerosis: Analysis of the Japanese subgroup in CASSIOPEIR study.
Kurumatani H; Okada K; Origasa H; Fujita T; Isono M; Nakamoto H
Ther Apher Dial; 2021 Oct; 25(5):551-564. PubMed ID: 33340238
[TBL] [Abstract][Full Text] [Related]
58. Effect of ketoconazole plus low-dose prednisone on progression of chronic renal failure.
Walser M; Hill S
Am J Kidney Dis; 1997 Apr; 29(4):503-13. PubMed ID: 9100038
[TBL] [Abstract][Full Text] [Related]
59. [The efficacy of kurantil and its effect on thrombocytic hemostasis in patients with chronic glomerulonephritis].
Kolesnyk MO; Lapchyns'ka II; Bielyts'ka HO
Lik Sprava; 1994; (9-12):145-8. PubMed ID: 7604556
[TBL] [Abstract][Full Text] [Related]
60. Effect of lemongrass tea consumption on estimated glomerular filtration rate and creatinine clearance rate.
Ekpenyong CE; Daniel NE; Antai AB
J Ren Nutr; 2015 Jan; 25(1):57-66. PubMed ID: 25440110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
